Skip to main content
. 2021 Aug 11;62:100105. doi: 10.1016/j.jlr.2021.100105

Fig. 4.

Fig. 4

Consequences of the LeprL536Hfs*6 mutation on liver and adipose tissue. Comparison of LeprL536Hfs*6 to C57BL/6N wildtype (wt) and Leprdb/db mice with regard to liver (A) triglyceride content (n = 4–5, unpaired t test, mean ± SD) and (B) glycogen content (n = 5, unpaired t test, mean ± SD). C: Histological differences as displayed in representative slides of liver stained with hematoxylin and eosin. Scale bars represent 100 μm. D–E: Comparison of adipose tissue between LeprL536Hfs*6 and Leprdb/db mice. D: Representative histological slides of subcutaneous adipose tissue (scAT) stained with hematoxylin and eosin. Scale bars represent 100 μm. Inguinal subcutaneous (sc) fat cell size distribution analyzed with Keyence BZ-X800 Analyzer and mean fat cell size calculated out of fat cell size (n = 600, unpaired t test, median ± min/max). E: Representative histological slides of epigonadal adipose tissue (epiAT) stained with hematoxylin and eosin. Scale bars represent 100 μm. EpiAT fat cell size distribution and mean fat cell size in epiAT from LeprL536Hfs*6 compared with Leprdb/db mice (n = 581–600, unpaired t test, median ± min/max).